iNtRON Biotechnology, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- -
A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011
Phase 1
Completed
- Conditions
- Acute Radiation Syndrome
- Interventions
- Drug: KMRC011 5μg or PlaceboDrug: KMRC011 10μg or PlaceboDrug: KMRC011 15μg or PlaceboDrug: KMRC011 25μg or PlaceboDrug: KMRC011 20μg or Placebo
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT03585803
- Locations
- 🇰🇷
Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of
A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Methicillin-Resistant Staphylococcus AureusHealthy VolunteersAnti-Bacterial AgentsMethicillin-Sensitive Staphylococcus Aureus Infection
- Interventions
- Other: INT200-PlaceboBiological: N-Rephasin® SAL200
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03446053
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Phase IIa Clinical Study of N-Rephasin® SAL200
Phase 2
Terminated
- Conditions
- Staphylococcus Aureus BacteremiaAnti-Bacterial Agents
- Interventions
- Other: PlaceboBiological: N-Rephasin® SAL200
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03089697
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Anti-Bacterial AgentsHealthy VolunteersMethicillin-Resistant Staphylococcus Aureus
- Interventions
- Biological: N-Rephasin® SAL200Other: INT200-Placebo
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Intron Biotechnology, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01855048
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath